Saeed, A., Xu, R., Singh, H., Henry, J. T., Spira, A. I., DeVito, N. C., Uboha, N. V., Castillo, D. R., Fei, N., Hanna, D., Wu, H., Tao, M., Liu, Z., Chen, K., McGregor, G. H., Das, S., Zou, H., Wang, M., Laeufle, R., Overman, M. J. (2026). Spevatamig (PT886), a claudin 18.2 (CLDN18.2)/CD47 bispecific antibody, in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4192